LAX.SH
SANOFI CONS HEALTHC IND L·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
3,262.8
-2.81%52W Range
Market Cap
₹7,514.43 Cr
Traded: ₹7.88 Cr (0.10%) 0.0x
Free Float: ₹631.96 Cr (1.25% of FF traded)
Volume · 60D trend
23.61 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | -- | -- | +38.0% | -- |
| ROE | -- | -- | +84.0% | -- | -- | -- |
| Return | -- | -- | -- | -5.0% | -- | -- |
| Profit | -- | -- | -- | -- | +35.0% | -- |
Quarterly Results
Mar 2024
Dec 2023
Sep 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 229 | 251 | 234 | 221 | 173 | 171 | 160 | 172 | 222 | 225 | 210 |
| Expenses | 146 | 140 | 161 | 149 | 151 | 109 | 109 | 97 | 109 | 140 | 135 | 116 |
| Operating Profit | 89 | 89 | 90 | 85 | 70 | 64 | 62 | 63 | 64 | 82 | 90 | 95 |
| Other Income | 6 | 6 | 5 | 3 | 12 | 5 | 2 | 3 | -24 | 3 | 1 | 1 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 92 | 91 | 90 | 84 | 79 | 67 | 63 | 61 | 39 | 84 | 90 | 95 |
| Tax % | 25.0% | 25.0% | 27.0% | 25.0% | 23.0% | 25.0% | 29.0% | 26.0% | 25.0% | 25.0% | 24.0% | 25.0% |
| Net Profit | 69 | 68 | 66 | 63 | 61 | 50 | 44 | 45 | 29 | 63 | 68 | 71 |
| Exceptional Items | 0 | 0 | 0 | 0 | 7 | 0 | -3 | -1 | -24 | 0 | -2 | 0 |
| EPS (Rs) | 29.9 | 29.4 | 28.9 | 27.3 | 26.4 | 21.7 | 19.2 | 19.5 | 12.6 | -- | -- | -- |
| Sales Growth (YoY) | -- | 32.8% | 47.0% | 46.3% | 28.2% | -22.1% | -24.0% | -24.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | -8.8% | 7.3% | 5.9% | 27.8% | 1.2% | 6.9% | -7.0% | -22.5% | -1.3% | 7.1% | -- |
| OP Growth (YoY) | 27.1% | 39.1% | 45.2% | 34.9% | 9.4% | -22.0% | -31.1% | -33.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | 0.0% | -1.1% | 5.9% | 21.4% | 9.4% | 3.2% | -1.6% | -1.6% | -22.0% | -8.9% | -5.3% | -- |
| Profit Growth (YoY) | -- | 36.0% | 43.0% | 37.0% | 23.0% | -20.0% | -33.0% | -36.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 35.6% | 50.0% | 39.8% | 109.4% | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 2.0% | 5.7% | 3.6% | 21.4% | 12.8% | -1.5% | 55.2% | -- | -- | -- | -- |
| OP Margin | -- | 38.9% | 35.9% | 36.3% | 31.7% | 37.0% | 36.3% | 39.4% | 37.2% | 36.9% | 40.0% | 45.2% |
| Net Margin | -- | 29.7% | 26.3% | 26.9% | 27.6% | 28.9% | 25.7% | 28.1% | 16.9% | 28.4% | 30.2% | 33.8% |
| Material Cost % | 23.9% | 24.5% | 27.2% | 26.4% | 27.7% | 22.5% | 24.6% | 24.2% | 26.4% | 27.1% | 27.1% | 28.9% |
| Employee Cost % | 13.3% | 14.4% | 14.1% | 13.6% | 14.5% | 17.1% | 16.2% | 17.1% | 14.4% | 10.3% | 8.6% | 10.3% |
| P/S | 7.91 | 11.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 28.25 | 42.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 21.59 | 42.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Unaudited ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026 is enclosed.
Intimation for Closure of Trading Window.
Unaudited Financial Results for the quarter and half year ended June 30, 2026 is enclosed.
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve the Unaudited ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 3oth June 2026 is enclosed.
Appointment of Statutory Auditor of the Company.
Please find eclosed Voting Results and Consolidated Scrutinizer''s Report of the 3rd Annual General Meeting held on 26th June 2026
Intimation for Closure of Trading Window.
Please find enclosed summary of proceeding of the 3rd Annual General Meeting of the Company held today.
Please find enclosed Annual Report for Financial Year 2025.
Business Responsibility and Sustainability Report for FY 2025 is enclosed.
Notice of 3rd AGM of the Company is enclosed
Please find enclosed copies of newspaper advertisements regarding convening of 3rd Annual General Meeting of the Company scheduled to be held on 26th June 2026, through VC/OAVM facility.
This is to inform you that the 3rd Annual General Meeting of the Company will be held on Friday, 26th June 2026 through VC/OAVM facility.
The Register of Member and Share Transfer Book of the Company will remain closed from Saturday, 20th June 2026 to Friday, 26th June 2026.
The record date for payment of final dividend for FY 2025 is Friday, 19th June 2026
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors of the Company to fill the casual vacancy and hold office for a period of 5 (five) consecutive ....
Appointment of M/s. Price Waterhouse & Co Chartered Accountants LLP as the Statutory Auditors of the Company to fill the casual vacancy and hold officer for a period of 5 (five) consecutive ....
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon India Mutual Fund
The Board of Directors at its meeting held on Tuesday, 28th April 2026, considered and approved the Unaudited Financial Results for the quarter ended 31st March 2026. In this regard, please ....
Copy of Newspaper Publication of Unaudited Financial Result for the quarter ended 31st March 2026 is enclosed.
This is to inform you that M/s. Kalyaniwalla & Mistry LLP, Chartered Accountants have tendered their resignation as Statutory Auditor of the Company with immediate effect.
We wish to inform you that the Board of Directors at its meeting held today i.e., Tuesday 28th April 2026, inter alia considered and approved the Unaudited Financial Results for the quarter ....
Unaudited Financial Results for the quarter ended March 31, 2026 is enclosed.
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2026 ,inter alia, to consider and approve the Unaudited ....
Please find enclosed Voting Results for Postal Ballot Notice dated 25th February 2026
Please find enclosed Report of Scrutinizer dated 23rd April 2026 issued by M/s. MMJB & Associates LLP
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2026 is enclosed.
The transcript of the Institutional Investor Meet held on Tuesday, 24th March 2026 is enclosed.
The video recording of SCHIL Institutional Investor Meet held on Tuesday, 24th March 2026 has been uploaded on the website of the Company.
Intimation for Closure of Trading Window
Sanofi Consumer Healthcare India Ltd has submitted to BSE a copies of the Postal Ballot Notice of the Company published on March 24, 2026 in the newspapers.
Copy of Investor Presentation is enclosed.
Intimation of Dispatch of Postal Ballot Notice to the Shareholders
Intimation of Schedule of Institutional Investor Meet
Submission of Annual Secretarial Compliance Report for the Financial Year ended 31st December 2025
Newspaper Publication of Audited Financial Results for the Quarter and Financial Year ended 31st December 2025
The Board of Directors at its meeting held today designated Ms. Nupur Gurbaxani, Director, Brand & Innovation as Senior Management Personnel of the Company
The Board of Directors at its meeting held today considered and approved the Audited Financial Statements for the quarter and Financial Year ended 31st December 2025. In this regard please ....
The Board of Directors at its meeting held today designated Mr. Viral Shah, Director, External Manufacturing as Senior Management Personnel of the Company.
The Board of Directors at its meeting held today approved the re-appointment of M/s. Kishore Bhatia & Associated as the Cost Auditor of the Company for the Financial Year ending 31st December 2026
The Board of Directors at its meeting held today approved final dividend of Rs. 75 per equity share having face value of Rs. 10 each for the Financial Year ended 31st December 2025
The Board of Directors at its meeting held today considered and approved the Audited Financial Statements of the Company for the quarter and financial year ended 31st December 2025
The Board of Directors at its meeting held today considered and approved the Audited Financial Statements of the Company for the quarter and financial year ended 31st December 2025
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve Intimation ....
Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve the Audited ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2025 is enclosed.
Intimation for Closure of Trading Window
Newspaper publication for the quarter and nine months ended Unaudited Financial Results 30 September 2025
Held by ETFs
2 ETFs hold sanoficonr · sorted by weight
Held by Mutual Funds
24 schemes hold sanoficonr · sorted by weight